Severe hemolysis after plasma transfusion in a neonate with necrotizing enterocolitis, Clostridium perfringens infection, and red blood cell T-polyagglutination

Transfusion. 2017 Nov;57(11):2571-2577. doi: 10.1111/trf.14196. Epub 2017 Jun 22.

Abstract

Background: Red blood cell (RBC) Thomsen-Friedenreich antigen exposure (T activation) in infants with necrotizing enterocolitis (NEC) has occasionally been associated with posttransfusional intravascular hemolysis thought to be due to anti-T antibodies in the donor plasma.

Study design and methods: We describe an infant with NEC and Clostridium perfringens infection complicated by severe hemolysis after plasma transfusion. After this case, infants with confirmed NEC were prospectively evaluated for T activation. We checked for hemolysis in patients with T activation receiving plasma-containing blood products.

Results: The infant had received 80 mL of fresh-frozen plasma (FFP). His RBCs displayed strong T activation, and agglutination was observed with four of six ABO-compatible FFP units. A direct antiglobulin test was negative. IgM-class anti-T antibodies were present in small amounts (titer of 8) in the transfused FFP. Anti-T antibodies from the blood donor were not hemolytic in vitro. In the prospective study, T activation was observed in three of 28 infants with NEC (11%). One infant presented moderate T activation and two infants presented very strong T activation but only moderate decreases in sialic acid expression on the RBC membrane. These three infants presented no signs of hemolysis after transfusion with unwashed blood products or FFP.

Conclusion: Anti-T antibodies are unlikely to be the etiologic factor for the hemolytic reactions observed in infants with NEC and T activation. Massive RBC desialylation and the direct action of bacterial toxins are more probable causes. Strict avoidance of plasma-containing blood products does not seem justified in these infants.

Publication types

  • Case Reports
  • Observational Study

MeSH terms

  • Adult
  • Antibodies / blood
  • Antibodies / immunology
  • Antigens, Tumor-Associated, Carbohydrate / immunology*
  • Bacterial Proteins / pharmacology
  • Blood Donors
  • Cefotaxime / administration & dosage
  • Cefotaxime / toxicity
  • Clostridium Infections / complications*
  • Clostridium Infections / microbiology
  • Clostridium perfringens / chemistry
  • Clostridium perfringens / enzymology
  • Enterocolitis, Necrotizing / complications*
  • Erythrocytes / immunology
  • Female
  • Hemolysis / immunology*
  • Humans
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Male
  • Middle Aged
  • Plasma Exchange / adverse effects*
  • Prospective Studies

Substances

  • Antibodies
  • Antigens, Tumor-Associated, Carbohydrate
  • Bacterial Proteins
  • Thomsen-Friedenreich antigen
  • Thomsen-Friedenreich antibodies
  • Cefotaxime